and Klippel-Trenaunay (KTS) syndromes are caused by somatic gain-of-function mutations in PIK3CA, encoding a catalytic subunit of phosphoinositide 3-kinase. Affected tissue is needed to find mutations, as mutant alleles are not detectable in blood. Because some patients with CLOVES develop Wilms tumor, we tested urine as a source of DNA for mutation detection.
disease-causing PIK3CA mutations have been identified in 67% to 95% of participants clinically suspected of having PROS. 6, 10 When affected tissue-white blood cell (WBC) paired-DNA samples have been studied, PIK3CA mutations are most often found only in the affected tissue. 10 This may be due to strongly activating PIK3CA mutations being completely selected against by WBCs or their stem cell precursors. Therefore, WBC DNA cannot be used to search for mutations in most persons suspected of having PROS. 1, 10 Not yet known is the rate of detecting PROS-causing mutations in other "unaffected" tissues, because few affected-unaffected tissue sample pairs have been analyzed. Thus, current methods for reliably detecting PIK3CA mutations in persons suspected of PROS require a biopsy or surgical collection of affected tissue. Screening DNA present in urine could enable non-invasive PIK3CA mutation identification, but previous studies of PROS patients have not searched for mutations in urine DNA. 1, 10, 11 Many somatic PIK3CA mutations that cause PROS are also common somatic mutations in cancer. For example, a somatic missense mutation affecting the 1047th amino acid residue of PIK3CA (p.
H1047R) was found in 15 of 162 individuals with PROS 10 and in 160 of 1462 breast cancer specimens (cancer.sanger.ac.uk; accessed
July 27, 2017). 12 Despite the frequent occurrence of somatic PIK3CA mutations in tumors, there are only a few case reports of individuals with mutation-confirmed PROS developing cancer. 3, 6, 13, 14 This may be because of the short period of follow-up available for most patients with PROS or because PIK3CA missense mutations enhance tumor growth but do not cause cell transformation.
Wilms tumor has been confirmed in 4 children and nephroblastomatosis confirmed in 2 children with PROS who have somatic PIK3CA
mutations. 3, 6, 13, 14 In patients for whom clinical information has been published, most of these individuals' phenotypic features fit best with the CLOVES syndrome subgroup. 3, 6, 13, 15, 16 Additional case reports of Wilms tumor arising in individuals with KTS 17, 18 and MCAP 19, 20 were published before CLOVES syndrome was described 21, 22 and before somatic PIK3CA mutations were associated with CLOVES, 3 KTS, 6 and MCAP. 5 These observations led us to test whether urine DNA contains detectable PIK3CA mutations in individuals with the CLOVES and KTS subgroups of PROS. One of our study participants with CLOVES had previously had a Wilms tumor resected, 3 thereby enabling us to determine whether this tumor is comprised of PIK3CA mutant cells. 6 Therefore, we used these same ddPCR assays to screen DNA extracted from urine and from the Wilms tumor. If ≥3 (3 or more) mutant allelecontaining amplimers were detected in a urine DNA ddPCR assay or if a participant had a mutation previously identified using affected tissue DNA, then the urine DNA ddPCR assay was repeated. We also used WBC DNA from healthy individuals without PROS to determine the rate at which mutant amplimer-containing droplets appeared among the total droplets (~14 000) in an assay when only wild-type DNA was used as template. 6 Furthermore, we used urine DNA samples from 8 persons with known PIK3CA mutations to determine the rate at which mutant amplimer-containing droplets appeared in ddPCR assays designed for the other mutations. After determining these "false positive" rates, we used the Poisson estimation to calculate the P value for observing greater than or equal to a specified number of mutant amplimer-containing droplets in a ddPCR assay when no actual mutant alleles are present.
| MATERIALS AND METHODS

| Participant ascertainment
| Determination of renal-urinary involvement
Clinical records, including radiology reports of abdominal magnetic resonance imaging (MRI) and/or ultrasound studies, were reviewed for each participant with CLOVES syndrome. Presence of any of the following features/findings was considered evidence of renal-urinary system involvement: hydronephrosis, renal asymmetry or bilateral enlargement seen on imaging, bladder wall involvement observed by cystoscopy, or recurrent hematuria.
| RESULTS
We observed that when DNA from healthy individuals or DNA from individuals with a different PIK3CA mutation was used as template, each of the ddPCR assays yielded mutant amplimer-containing droplets at frequencies ≤0.008%. Using 0.008% as the rate of observing mutant amplimer-containing droplets when no mutant alleles are present, the probability of observing ≥3 and ≥6 mutant amplimercontaining droplets out of 14 000 total droplets is .10 and .001, respectively.
We identified PIK3CA hotspot mutations (P < .05) in urine DNA samples from 8 of 17 participants with CLOVES and 0 of 24 participants with KTS (Table 1 ).
In 6 of the 17 CLOVES participants, the observed numbers of mutant droplets remained significant after correcting for multiple hypothesis testing (P < .0001). For 8 participants with CLOVES, we had previously identified their causal PIK3CA mutation using ddPCR with DNA from affected tissue as template. 
| DISCUSSION
Using an assay which targets 5 commonly found PIK3CA mutations, we confidently detected causal mutations in urine DNA samples from 6 of 17 individuals with CLOVES syndrome, including 4 of 8 individuals in whom we previously detected a mutation in affected tissue.
These data indicate that screening DNA from a urine sample can find causal mutations without having to biopsy affected tissue in >35% of individuals with CLOVES syndrome. The abundance of mutant alleles in the urine is probably lower than that in clinically affected tissue, because the mutant allele frequency in the urine DNA from our participants ranged from 0.25% to 7.69%, which is lower than the 1.5%
to 32% range we observed when affected tissue was tested. 6 Interestingly
clinical or radiographic signs, suggesting that clinical kidney or urinary tract involvement need not be present to identify mutant alleles in urine DNA.
Four participants with CLOVES who had a known PIK3CA mutation in their affected tissue did not have the mutation confidently detected in urine DNA. All 4 of these participants had fewer than 2500 amplimer-containing droplets in the urine DNA sample, so a low frequency mutation could be missed or indistinguishable from a false positive result. For example, participants CL-U12 and CL-U15/ 16 each had mutant amplimer-containing droplets in urine DNA, but at frequencies too low to achieve statistical significance.
We employed ddPCR assays to search for 5 different mutations in urine DNA because we previously found that approximately 90%
of individuals with CLOVES syndrome or KTS had one of these 5 mutations in their affected tissue. 6 However, in another patient cohort, these 5 mutations accounted for only 33% of PIK3CA mutations found in individuals with CLOVES syndrome and 66% of PIK3CA mutations found in individuals with KTS. 10 At present, we do not know why mutation frequencies differ between these cohorts.
Given this difference between cohorts, the detection rate for the 5 PIK3CA mutations we sought in urine DNA may also differ. Nevertheless, as ddPCR is sensitive, specific, and inexpensive to perform, we suggest that it is considered as an initial screening method for PIK3CA when affected tissue is unavailable. If no mutation is found, then proceeding to methods that can interrogate the entire PIK3CA gene such as single molecule multiplex inversion probe or ultradeep next-generation sequencing would be a next, but more costly, step.
The same strategy can be applied if affected tissue becomes available; currently, because there are no mutation-specific targeted therapies for persons with PROS, we do not think performing ddPCR first will negatively affect clinical care by delaying the molecular diagnosis.
We did not detect mutant PIK3CA alleles in any of the 24 urine DNA samples from participants with KTS. Three of these individuals had PIK3CA mutations previously identified in their affected tissue.
At present, we do not know why mutations were found in the urine from multiple persons with CLOVES and from no individual with KTS.
One possibility is in how we clinically distinguish CLOVES from KTS. Abbreviations: CLOVES, congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies; ddPCR, droplet digital polymerase chain reaction. Mutant alleles detected in the urine DNA that probably represent true positive results are highlighted in bold. Participants with PIK3CA mutations previously identified using affected tissue DNA are indicated (*), as are the ages when participants with CLOVES syndrome provided urine samples. Clinical signs and imaging-based findings are noted for individuals who had documented kidney/urinary system involvement. The amino acid designation for the mutation detected in a participant's affected tissue and/or urine DNA is provided, along with ddPCR assay results indicating the total number of amplimer-containing droplets, the number of mutant amplimer-containing droplets, the percentage of amplimer-containing droplets with mutant alleles, the total number of droplets (amplimer-containing or not), and the P value that the observed result is a false positive. For the 4 participants in whom a mutation was present in affected tissue DNA and not confidently detected in the urine DNA specimen, the total numbers of ddPCR droplets, amplimer-containing droplets, and mutant amplimer-containing droplets evaluated in the urine DNA sample are provided. Since 5 different ddPCR assays were performed on each participant's urine sample, the mean number of amplimer-containing droplets for all 5 assays is provided. Since no KTS urine sample contained ≥3 mutant amplimer-containing droplets, only the mean number of amplimer-containing droplets for all 5 assays is provided. Single urine samples were collected from most participants. Participants whose ddPCR assays failed for unknown reasons are indicated ( # ).
of CLOVES. 3, 6, 13, 15 One of these children participated in this study.
Her Wilms tumor was resected when she was 2 years old and she provided a urine sample for this study when she was 4 years old and tumor-free. It is interesting to note that she had a mutant allele frequency in her urine DNA specimen of 2.9%, which raises the question of whether higher frequencies of PIK3CA mutant alleles in urine ; however, each report was published before CLOVES syndrome was described, 22 which in retrospect seems the more probable diagnosis in each patient.
| CONCLUSIONS
PIK3CA mutations were confidently detected in the urine DNA of >35% of patients with CLOVES syndrome. As urine DNA can be col- A ×200 magnification H&E stained cryostat section of the Wilms tumor, which had been treated with chemotherapy prior to surgical excision, showing epithelial differentiation with tubular profiles. C, Dot plot graphing fluorescence intensities of individual droplets for the p.H1047R droplet digital polymerase chain reaction (ddPCR) assay performed using DNA from the Wilms tumor. Blue dots, green dots, and black dots indicate droplets containing mutant amplimer, wild-type amplimer, and no amplimer, respectively. Some droplets containing mutant and wildtype amplimer are present in the right upper quadrant. Note, 12 682 droplets contain no amplimer; of the 1119 total amplimer-containing droplets, 474 contain mutant amplimer, consistent with approximately 84% of the cells within the tumor having a PIK3CA mutation
